Summit Therapeutics Inc (SMMT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$15.47-0.51%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Summit Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	3.97M
EPS	—	-0.362
Annual ending 2026-12-31
Revenue	—	3.66M
EPS	—	-1.16
Annual ending 2027-12-31
Revenue	—	59.54M
EPS	—	-1.133

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance ivonescimab FDA approval process	Summit Therapeutics aims to get FDA approval for ivonescimab, a key drug.	Improving	No FDA approval or major regulatory setback by end of 2026	Qualitative: No FDA decision yet; $2B AZ investment & Phase III progress AstraZeneca invested $2B in Sept 2026. Phase III progress reported. No FDA approval or major regulatory setback observed. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The FDA accepted Summit's BLA for ivonescimab in January 2026 with a PDUFA date set for November 14, 2026. Updated overall survival data from the HARMONi trial continue to support the application. The trajectory is delivering regulatory progress consistent with management’s stated timeline. Delivery assessment Oct 24, 2026
Manage operating cash flow and net losses	A primary condition in Summit Therapeutics Inc's published investment case. The stated target is Reduce operating cash flow burn below $100 million per quarter by FY27.	Recovered	Operating cash flow burn exceeds $100 million per quarter beyond FY27	Cash from operations: $-167.779M FY2026-Q2; GAAP. Published target: Reduce operating cash flow burn below $100 million per quarter by FY27. Target period is not explicitly aligned with this observation. Source published Jul 23, 2026-167,779,398 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. GAAP net losses were $189.4M in 2026-Q1 and increased to $215.7M in 2026-Q2, reflecting expanded clinical development costs. Operating expenses increased accordingly. The trajectory shows management balancing clinical expansion with cost control, consistent with stated priorities. Delivery assessment Oct 24, 2026
Raise sufficient capital without dilutive setbacks	A supporting condition in Summit Therapeutics Inc's published investment case. The stated target is Complete capital raise exceeding $400 million by end 2026.	Intact	Failure to raise at least $400 million by end 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.13

$-0.88 → $-1.13 · observed estimates

FY2027 revenue$0.06B

$0.04B → $0.06B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.88	$42,122,790	10 / 14
2026-07-25	$-0.91	$42,475,650	10 / 14
2026-07-26	$-1.10	$63,404,495	8 / 10
2026-07-27	$-1.10	$63,404,495	8 / 10
2026-07-28	$-0.89	$44,069,070	11 / 15
2026-07-29	$-0.89	$44,258,330	11 / 15
2026-07-30	$-1.10	$63,404,495	8 / 10
2026-07-31	$-1.10	$63,404,495	8 / 10
2026-08-01	$-1.10	$63,404,495	8 / 10
2026-08-02	$-1.10	$63,404,495	8 / 10
2026-08-03	$-1.10	$63,404,495	8 / 10
2026-08-04	$-0.89	$44,258,330	11 / 15
2026-08-05	$-1.10	$63,404,495	8 / 10
2026-08-06	$-0.89	$44,258,330	11 / 15
2026-08-08	$-1.10	$63,404,495	8 / 10
2026-08-09	$-0.89	$44,258,330	11 / 15
2026-08-10	$-1.10	$63,404,495	8 / 10
2026-08-12	$-0.89	$44,245,530	11 / 15
2026-08-13	$-1.10	$63,404,495	8 / 10
2026-08-14	$-1.10	$63,404,495	8 / 10
2026-08-15	$-1.10	$63,404,495	8 / 10
2026-08-16	$-1.10	$63,404,495	8 / 10
2026-08-17	$-1.10	$63,404,495	8 / 10
2026-08-18	$-1.10	$63,404,495	8 / 10
2026-08-19	$-1.10	$63,404,495	8 / 10
2026-08-20	$-1.15	$59,526,862	8 / 10
2026-08-21	$-1.15	$59,526,862	8 / 10
2026-08-22	$-1.15	$59,526,862	8 / 10
2026-08-23	$-1.15	$59,526,862	8 / 10
2026-08-24	$-1.15	$59,526,862	8 / 10
2026-08-25	$-1.15	$59,526,862	8 / 10
2026-08-26	$-1.16	$59,526,862	8 / 10
2026-08-27	$-1.16	$59,526,862	8 / 10
2026-08-28	$-1.16	$59,526,862	8 / 10
2026-08-29	$-1.16	$59,526,862	8 / 10
2026-08-30	$-1.16	$59,526,862	8 / 10
2026-08-31	$-1.16	$59,526,862	8 / 10
2026-09-01	$-1.16	$59,526,862	8 / 10
2026-09-02	$-1.16	$59,526,862	8 / 10
2026-09-03	$-1.16	$59,529,035	8 / 10
2026-09-04	$-1.16	$59,535,702	8 / 10
2026-09-05	$-1.16	$59,535,702	8 / 10
2026-09-06	$-1.16	$59,535,702	8 / 10
2026-09-07	$-1.16	$59,535,702	8 / 10
2026-09-08	$-1.16	$59,535,702	8 / 10
2026-09-09	$-1.16	$59,535,702	8 / 10
2026-09-10	$-1.16	$59,535,702	8 / 10
2026-09-11	$-1.16	$59,535,702	8 / 10
2026-09-12	$-1.16	$59,535,702	8 / 10
2026-09-13	$-1.16	$59,535,702	8 / 10
2026-09-14	$-1.16	$59,535,702	8 / 10
2026-09-15	$-1.16	$59,535,702	8 / 10
2026-09-16	$-1.16	$59,535,702	8 / 10
2026-09-17	$-1.16	$59,535,675	8 / 10
2026-09-18	$-1.16	$59,535,675	8 / 10
2026-09-19	$-1.16	$59,535,675	8 / 10
2026-09-20	$-1.16	$59,535,675	8 / 10
2026-09-21	$-1.16	$59,535,675	8 / 10
2026-09-22	$-1.16	$59,535,675	8 / 10
2026-09-23	$-1.16	$59,535,675	8 / 10
2026-09-24	$-1.16	$59,535,675	8 / 10
2026-09-25	$-1.16	$59,535,675	8 / 10
2026-09-26	$-1.16	$59,535,675	8 / 10
2026-09-27	$-1.16	$59,535,675	8 / 10
2026-09-28	$-1.16	$59,535,675	8 / 10
2026-09-29	$-1.16	$59,535,675	8 / 10
2026-09-30	$-1.16	$59,533,502	8 / 10
2026-10-01	$-1.14	$59,533,502	8 / 10
2026-10-02	$-1.13	$59,533,502	8 / 10
2026-10-03	$-1.13	$59,533,502	8 / 10
2026-10-04	$-1.13	$59,533,502	8 / 10
2026-10-05	$-1.13	$59,533,502	8 / 10
2026-10-06	$-1.13	$59,533,502	8 / 10
2026-10-07	$-1.13	$59,533,328	8 / 10
2026-10-08	$-1.13	$59,533,328	8 / 10
2026-10-09	$-1.13	$59,533,328	8 / 10
2026-10-10	$-1.13	$59,533,328	8 / 10
2026-10-11	$-1.13	$59,533,328	8 / 10
2026-10-12	$-1.13	$59,533,328	8 / 10
2026-10-13	$-1.13	$59,533,328	8 / 10
2026-10-14	$-1.13	$59,533,328	8 / 10
2026-10-15	$-1.13	$59,533,328	8 / 10
2026-10-16	$-1.13	$59,533,328	8 / 10
2026-10-17	$-1.13	$59,533,328	8 / 10
2026-10-18	$-1.13	$59,535,500	8 / 10
2026-10-19	$-1.13	$59,535,500	8 / 10
2026-10-20	$-1.13	$59,535,502	8 / 10
2026-10-21	$-1.13	$59,535,502	8 / 10
2026-10-22	$-1.13	$59,535,502	8 / 10
2026-10-23	$-1.13	$59,535,502	8 / 10
2026-10-24	$-1.13	$59,535,502	8 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	12	5	2
2026-06-01	10	5	2
2026-07-01	10	5	2
2026-08-01	10	7	2
2026-09-01	11	7	0
2026-10-01	11	6	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 6 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 25–Oct 24 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 1

$20.00New observation · no comparable prior

JefferiesSep 29 · prior Jul 24

$15.00 → $30.00+100.0%

Goldman SachsSep 29

$41.00New observation · no comparable prior

$0$22.55$45.10

1 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage operating cash flow and net lossesCash from operations: $-167.779M
Raise sufficient capital without dilutive setbacksDirect metric needs a verified mapping

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-52.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Summit Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-development story, not a proven earnings compounder. The long-term thesis is still active, but its current state is watch, with recent performance below its industry cohort.

What's priced into Summit Therapeutics Inc

The evidence snapshot provides no valuation or explicit market-expectations data, so whether SMMT is cheap or expensive versus peers cannot be assessed. Price reaction to the recent thesis has been muted, and no fragility gates fired.

What the fundamentals likely do

Over the multi-year view, progress depends on ivonescimab trials, regulatory review, and collaboration studies. Management has advanced these priorities, including FDA acceptance of the application, but progress is mixed and recent financial performance is weak. Near term, elevated risk of another earnings miss and a weakening jobs trend are concerns.

What Summit Therapeutics Inc hinges on

A key near-term milestone is the FDA decision on ivonescimab for non-small-cell lung cancer, scheduled for November 14, 2026. The longer-term case also depends on clinical results and collaboration progress. Healthcare-sector support could strengthen if bellwethers keep reporting strong results, but weaken if they miss or guide lower.